198 related articles for article (PubMed ID: 25948798)
21. Molecular markers for prostatic cancer.
Castelli T; Cimino S; Magno C; Morgia G
Front Biosci (Elite Ed); 2010 Jan; 2(2):641-56. PubMed ID: 20036908
[TBL] [Abstract][Full Text] [Related]
22. Use of two gene panels for prostate cancer diagnosis and patient risk stratification.
Xiao K; Guo J; Zhang X; Feng X; Zhang H; Cheng Z; Johnson H; Persson JL; Chen L
Tumour Biol; 2016 Aug; 37(8):10115-22. PubMed ID: 26820133
[TBL] [Abstract][Full Text] [Related]
23. Predicting high-risk disease using tissue biomarkers.
Donovan MJ; Cordon-Cardo C
Curr Opin Urol; 2013 May; 23(3):245-51. PubMed ID: 23478499
[TBL] [Abstract][Full Text] [Related]
24. Biomarkers in prostate cancer management. Is there something new?
Carrion DM; Gómez Rivas J; Álvarez-Maestro M; Martínez-Piñeiro L
Arch Esp Urol; 2019 Mar; 72(2):105-115. PubMed ID: 30855011
[TBL] [Abstract][Full Text] [Related]
25. Blood-based and urinary prostate cancer biomarkers: a review and comparison of novel biomarkers for detection and treatment decisions.
Hendriks RJ; van Oort IM; Schalken JA
Prostate Cancer Prostatic Dis; 2017 Mar; 20(1):12-19. PubMed ID: 27922627
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of New Tests and Interventions for Prostate Cancer Management: A Systematic Review.
Olleik G; Kassouf W; Aprikian A; Hu J; Vanhuyse M; Cury F; Peacock S; Bonnevier E; Palenius E; Dragomir A
J Natl Compr Canc Netw; 2018 Nov; 16(11):1340-1351. PubMed ID: 30442734
[No Abstract] [Full Text] [Related]
27. Promise and challenge: Markers of prostate cancer detection, diagnosis and prognosis.
Troyer DA; Mubiru J; Leach RJ; Naylor SL
Dis Markers; 2004; 20(2):117-28. PubMed ID: 15322319
[TBL] [Abstract][Full Text] [Related]
28. Biomarkers in prostate cancer surveillance and screening: past, present, and future.
Cary KC; Cooperberg MR
Ther Adv Urol; 2013 Dec; 5(6):318-29. PubMed ID: 24294290
[TBL] [Abstract][Full Text] [Related]
29. Molecular diagnosis of prostate cancer: are we up to age?
Bhavsar T; McCue P; Birbe R
Semin Oncol; 2013 Jun; 40(3):259-75. PubMed ID: 23806492
[TBL] [Abstract][Full Text] [Related]
30. The role of biomarkers in the assessment of prostate cancer risk prior to prostate biopsy: which markers matter and how should they be used?
Schmid M; Trinh QD; Graefen M; Fisch M; Chun FK; Hansen J
World J Urol; 2014 Aug; 32(4):871-80. PubMed ID: 24825472
[TBL] [Abstract][Full Text] [Related]
31. Urine TMPRSS2: ERG Fusion Transcript as a Biomarker for Prostate Cancer: Literature Review.
Sanguedolce F; Cormio A; Brunelli M; D'Amuri A; Carrieri G; Bufo P; Cormio L
Clin Genitourin Cancer; 2016 Apr; 14(2):117-21. PubMed ID: 26774207
[TBL] [Abstract][Full Text] [Related]
32. Tumor markers in prostate cancer I: blood-based markers.
Shariat SF; Semjonow A; Lilja H; Savage C; Vickers AJ; Bjartell A
Acta Oncol; 2011 Jun; 50 Suppl 1(Suppl 1):61-75. PubMed ID: 21604943
[TBL] [Abstract][Full Text] [Related]
33. An up-to-date catalogue of urinary markers for the management of prostate cancer.
Brönimann S; Pradere B; Karakiewicz P; Huebner NA; Briganti A; Shariat SF
Curr Opin Urol; 2020 Sep; 30(5):684-688. PubMed ID: 32701725
[TBL] [Abstract][Full Text] [Related]
34. A Rich Array of Prostate Cancer Molecular Biomarkers: Opportunities and Challenges.
Kohaar I; Petrovics G; Srivastava S
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31013716
[TBL] [Abstract][Full Text] [Related]
35. Using Genetic and Epigenetic Markers to Improve Differential Diagnosis of Prostate Cancer and Benign Prostatic Hyperplasia by Noninvasive Methods in Mexican Patients.
Sánchez BE; Aguayo A; Martínez B; Rodríguez F; Marmolejo M; Svyryd Y; Luna L; Muñoz LA; Jiménez MA; Sotomayor M; Vargas V F; Mutchinick OM
Clin Genitourin Cancer; 2018 Aug; 16(4):e867-e877. PubMed ID: 29571584
[TBL] [Abstract][Full Text] [Related]
36. The prognostic and predictive value of TMPRSS2-ERG gene fusion and ERG protein expression in prostate cancer biopsies.
Berg KD
Dan Med J; 2016 Dec; 63(12):. PubMed ID: 27910803
[TBL] [Abstract][Full Text] [Related]
37. A urine-based DNA methylation assay, ProCUrE, to identify clinically significant prostate cancer.
Zhao F; Olkhov-Mitsel E; Kamdar S; Jeyapala R; Garcia J; Hurst R; Hanna MY; Mills R; Tuzova AV; O'Reilly E; Kelly S; Cooper C; ; Brewer D; Perry AS; Clark J; Fleshner N; Bapat B
Clin Epigenetics; 2018 Nov; 10(1):147. PubMed ID: 30470249
[TBL] [Abstract][Full Text] [Related]
38. Urinary RNA-based biomarkers for prostate cancer detection.
Martignano F; Rossi L; Maugeri A; Gallà V; Conteduca V; De Giorgi U; Casadio V; Schepisi G
Clin Chim Acta; 2017 Oct; 473():96-105. PubMed ID: 28807541
[TBL] [Abstract][Full Text] [Related]
39. Semen miRNAs Contained in Exosomes as Non-Invasive Biomarkers for Prostate Cancer Diagnosis.
Barceló M; Castells M; Bassas L; Vigués F; Larriba S
Sci Rep; 2019 Sep; 9(1):13772. PubMed ID: 31551516
[TBL] [Abstract][Full Text] [Related]
40. New biomarkers for diagnosis and prognosis of localized prostate cancer.
Chistiakov DA; Myasoedova VA; Grechko AV; Melnichenko AA; Orekhov AN
Semin Cancer Biol; 2018 Oct; 52(Pt 1):9-16. PubMed ID: 29360504
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
